News

Mirvetuximab soravtansine is currently being evaluated in the phase Ib/II FORWARD II study in combination with anticancer agents including Doxil (doxorubicin), Avastin (bevacizumab) and Paraplatin (carboplatin). The mirvetuximab

This is a follow-on investment from the foundation for achievement based on the development of a new pneumococcal vaccine which targets Streptococcus pneumoniae (pneumococcus) towards clinical testing. The

The drug can be taken in combination of sofosbuvir with or without ribavirin in genotypes 1 and 3. With this combination, three difficult to treat patient populations can

The milestone was triggered by Takeda surpassing annual ADCETRIS net sales of $200m in its territory during 2015. The milestone will be recognized as royalty revenue in the

The PDAC recommendation is based on the efficacy results from FOCUS and CONNECT studies, which were specifically designed to evaluate the effect of Brintellix on certain aspects of

This clinical trial is an open label dose-escalation and expansion study designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), tolerability, pharmacokinetics and

John Rundback, Medical Director of the Interventional Institute at Holy Name Medical Center in Teaneck, New Jersey enrolled the first patient. The trial will recruit additional patients at

ProForm Select aligns our solid-state, process chemistry and formulation development centers of excellence in Weert, The Netherlands, Germantown, Wisconsin and Wilmington, North Carolina. These groups are focused on

Freund Pharmatec, a wholly-owned Irish subsidiary of Freund Corporation, is a specialist drug delivery technology company focused on proprietary mini-encapsulation and layering technologies. Through this acquisition, Sigmoid will